Drug

2017 – Nano-sized cytochrome p450 3a4 inhibitors to block hepatic – Paolini et al.

Most drugs are metabolized by hepatic cytochrome P450 3A4 (CYP3A4), resulting in their reduced bioavailability. In this study, we present the design and evaluation of biocompatible nanocarriers trapping a natural CYP3A4-inhibiting compound. Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic CYP3A4 and leave drug-metabolizing enzymes in other organs undisturbed.

Continuer la lecture…

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

Congress: CLINAM, 23rd May 2011 – The development of new activatable drug nanocarriers, with multiple functionalities, presents a promising approach for cancer treatment. Improved drug delivery and controlled drug release at the tumor site may have considerable benefit by increasing treatment efficacy while reducing side effects and toxicity. Further, the possibility to monitor both nanocarrier accumulation and drug release via current clinical imaging techniques may be particularly relevant for an optimal treatment.

Continuer la lecture…

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

Congress: CLINAM, 23rd May 2011 – The development of new activatable drug nanocarriers, with multiple functionalities, presents a promising approach for cancer treatment. Improved drug delivery and controlled drug release at the tumor site may have considerable benefit by increasing treatment efficacy while reducing side effects and toxicity. Further, the possibility to monitor both nanocarrier accumulation and drug release via current clinical imaging techniques may be particularly relevant for an optimal treatment.

Continuer la lecture…

2010 – Combinations of proteins with Nano-Systems – Di Marco et al.

The latest development of protein engineering allows the production of proteins having desired properties and large potential markets, but the clinical advances of therapeutical proteins are still limited by their fragility. Nanotechnology could provide optimal vectors able to protect from degradation therapeutical biomolecules such as proteins, enzymes or specific polypeptides.

Continuer la lecture…

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer